ArticleAbdominal radiology (New York)2024

A real-world study of tyrosine kinase inhibitors plus anti-PD-1 immunotherapy with or without chemoembolization for hepatocellular carcinoma patients with main portal vein invasion.

Ze Song et al.PubMed ↗Publisher ↗

No numbers read from the abstract.